Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Single-dose, Randomized, Two-period, Two-treatment, Two-sequence, Crossover Bioequivalence Study of Amlodipine and Losartan Versus Two Co-administration of Amlodipine and Losartan in Healthy Caucasian Subjects.

Next Previous
Search
Trial Profile

A Single-dose, Randomized, Two-period, Two-treatment, Two-sequence, Crossover Bioequivalence Study of Amlodipine and Losartan Versus Two Co-administration of Amlodipine and Losartan in Healthy Caucasian Subjects.

Status: Completed
Phase of Trial: Phase I

Latest Information Update: 03 May 2011

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Amlodipine/losartan (Primary) ; Amlodipine; Losartan
  • Indications Angina pectoris; Diabetic nephropathies; Heart failure; Hypertension
  • Focus Pharmacokinetics

    • Most Recent Events

    • 26 Apr 2011 Actual end date (Nov 2010) added as reported by ClinicalTrials.gov.
    • 10 Jan 2011 Hanmi Pharmaceuticals is planning to submit application for marketing approval of Amosartan in European countries in late 2011, according to a company media release.
    • 10 Jan 2011 Status changed from recruiting to completed, according to a Hanmi Pharmaceuticals media release.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top